TBX3 and metabolic dysfunction-associated steatotic liver disease: Both fatty acid oxidation and VLDL secretion are impacted by the presence and severity of MASLD, so it is difficult to attribute transcriptional differences directly to loss of Tbx3 versus differences caused by reduced MASLD.